Drug Approval | January 14, 2022
Glenmark receives U.S. FDA approval for Ryaltris
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The study will be published on the pre-print server, medRXiv, shortly
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
The drug is priced at Rs 2000 for a course of 40 tablets
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Subscribe To Our Newsletter & Stay Updated
